AIM RULE 26
The following information is disclosed in accordance with AIM Rule 26.
Last updated 1 September 18.
Amryt is a commercial stage pharmaceutical company focused on acquiring, developing and commercialising innovative new treatments that help improve the lives of patients with rare and orphan diseases.
Our mission is to be a world leader in rare and orphan diseases.
Click here to find out more about us.
|Incorporation & Registered Office||
Country of Incorporation:
Main country of operation:
Company registration number:
Harry Stratford (Non-Executive Chairman)
The Quoted Companies Alliance (QCA) has published a corporate governance code for small and medium sized quoted companies, which includes a standard of minimum best practice for AIM companies and recommendations for reporting corporate governance matters (QCA Code). The QCA code is constructed around ten broad principles which the Company has chosen to apply to ensure good governance practices are in place.
Information on Corporate Governance can be found here.
|UK Takeover code||
The Company is subject to the UK City Code on Takeovers and Mergers.
|Annual and Half Yearly Reports & Accounts||
Annual and Half Yearly Reports & Accounts can be found here.
RNS announcements can be found here.
|Details of Restrictions on the Transfer of Securities||
There are no restrictions on the transfer of ordinary shares.
|Details of any other Exchanges or Trading Platform||
The shares of the Company are traded on the AIM market operated by the London Stock Exchange and the Enterprises Securities Market of the Irish Stock Exchange (Euronext Dublin).
|Shares & Significant Shareholders||
Total number of shares issued: 274,817,283
The identity and shareholdings of the Company’s significant shareholder can be found here.
|Shares not in public hands||
Pursuant to the AIM rules, and insofar as the Company is aware, as at 1 September 2018, 43.5% of the Company’s AIM Securities were not in public hands.
Page last updated: 21 September 2018